Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib PK in Renal Impairment
NCT02096718Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of afatinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Curve from time zero to the last quantifiable concentration up to 312 hours and Maximum Plasma Concentration up to 312 hours. Started May 2014; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02096718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096718.